Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the HKEX Technology 100 Index, marking a significant milestone in its index and data business development, reflecting the transformation of the Hong Kong market towards a technology-centric identity [1][2]. Group 1: Introduction of the Technology 100 Index - The HKEX Technology 100 Index is a broad-based stock index tracking the performance of the 100 largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [2][3]. - The index includes only stocks eligible for the Stock Connect program, catering to both international and mainland Chinese investors [2]. Group 2: Market Trends and Investor Sentiment - There has been a noticeable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [3]. - Data indicates a significant change in the market structure, with the market capitalization of technology stocks in the Stock Connect program rising from approximately 10% in 2014 to about 40% by 2025, with four out of the top ten companies being technology giants [3]. Group 3: Differentiation from Existing Indices - The HKEX Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 20 billion HKD [5][6]. - The index aims to meet diverse investor needs, providing a broader selection of technology stocks compared to existing indices [6]. Group 4: Future Developments and Performance - The HKEX plans to introduce more indices, including thematic indices, to further enhance its product offerings [8]. - The HKEX Technology 100 Index has shown strong performance, with a cumulative return of approximately 40% year-to-date, and returns of 45% and 55% over the past year and three years, respectively, highlighting the growth potential of the technology sector in the Hong Kong market [9].

证券时报记者 吴瞬 近日，香港交易及结算所有限公司（以下简称"港交所"）正式推出香港交易所科技100指数。作为港交 所推出的首只港股指数，这也是港交所指数及数据业务发展的一个重要里程碑。 对此，港交所市场主管余学勤近期接受证券时报记者专访时表示，港交所科技100指数是在香港市场结 构出现根本性转变之下推出的，科技已成为港股市场的新名片。他说："我们不会做市场上类似的东 西，我们更希望是把市场做大，给投资者更多选择。" 科技名片孕育新指数 据介绍，港交所科技100是一个宽基股票指数，追踪100家在港交所上市的市值最大科技公司表现，行业 涵盖六大创新主题，分别为人工智能、生物科技及制药、电动汽车及智能驾驶、信息科技、互联网和机 器人。指数的成份股皆为港股通合资格股票，以满足国际和中国内地投资者的投资需求。 "指数作为一个基本工具，很多海外交易所都有自身的指数业务，港交所如果自己做指数业务，灵活性 更大，也可以覆盖更多市场需求。更为关键的是，我们有优势，因为所有的交易数据，我们才是数据源 头。"余学勤坦言，近年来港交所一直在丰富产品生态圈，指数是不可缺少的一环，因为指数可以推动 与之挂钩的ETF、期货和期权产品的发 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking a significant milestone in its index and data business development, reflecting a fundamental shift in the market structure towards technology as a key sector [1][2]. Group 1: Introduction of the Technology 100 Index - The Technology 100 Index tracks the performance of 100 of the largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1]. - The index is designed to meet the investment needs of both international and mainland Chinese investors, as all constituent stocks are eligible for the Stock Connect program [1][2]. Group 2: Market Trends and Investor Interest - There has been a noticeable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [2]. - Data indicates that the market structure has transitioned from traditional industries to being dominated by technology companies, with the market capitalization of technology stocks in the Stock Connect program expected to rise from approximately 10% in 2014 to about 40% by 2025 [2]. Group 3: Differentiation from Existing Indices - The Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 20 billion HKD [3]. - The index aims to cater to diverse investor needs, providing a broader range of investment options compared to existing indices [3]. Group 4: Accessibility and Inclusion Criteria - All constituent stocks of the Technology 100 Index must meet the eligibility criteria for the Stock Connect program, ensuring ease of access for mainland fund companies [4]. - The index requires constituent stocks to have at least six months of listing history, but it also includes a rapid inclusion mechanism for representative new stocks that meet the criteria [4]. Group 5: Future Developments and Performance - The HKEX plans to introduce more indices, including thematic indices, to meet growing investor demand [5]. - The Technology 100 Index has shown strong performance, with a cumulative return of approximately 40% year-to-date as of November 30, 2025, and returns of 45% and 55% over the past year and three years, respectively, highlighting the growth potential of the technology sector in the Hong Kong market [5].

Core Viewpoint - The Hong Kong Stock Exchange has launched the Hong Kong Stock Exchange Technology 100 Index, which tracks the performance of the 100 largest technology companies listed on the exchange [1] Group 1: Index Overview - The Hong Kong Stock Exchange Technology 100 Index is the first index of its kind for Hong Kong stocks, focusing on major technology firms [1] - The index covers six major innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] Group 2: Constituent Stocks - Initial constituent stocks of the Technology 100 Index include major companies such as Tencent Holdings, Alibaba, Xiaomi Group, and Meitu [1] - The index features a rapid inclusion mechanism, allowing newly listed companies that meet specific criteria to be added outside the regular review cycle after being included in the Hong Kong Stock Connect trading [1]

Core Viewpoint - The healthcare stocks in mainland China have experienced a significant pullback since early last month, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index declining by 12% and 9% respectively, compared to a 2% drop in the Hang Seng Index and a 1% increase in the CSI 300 Index [1] Group 1: Market Influences - The decline in healthcare stocks is attributed to multiple factors, including heightened US-China tensions and increased geopolitical risk premiums prompting profit-taking by investors [1] - The introduction of a milder version of the US "Biosecurity Act" attached to next year's National Defense Authorization Act has raised uncertainties regarding pharmaceutical outsourcing services [1] - Concerns persist regarding potential increased regulation from the US, such as restrictions on authorized transactions with China or limitations on clinical data from China, which could impact the biotech and pharmaceutical sectors [1] Group 2: Market Sentiment and Valuation - The anticipated outcomes of the national medical insurance drug list price negotiations and the legislative progress of the "Biosecurity Act" are expected to influence market sentiment [1] - Despite the recent stock price declines, industry valuations and market expectations for business development transactions are returning to more reasonable levels, with no substantial deterioration in the industry's fundamental performance observed [1] - The recent pullback in stock prices may provide favorable conditions for performance in the upcoming year [1] Group 3: Preferred Stocks - The company identifies preferred stocks including CanSino Biologics (09926), Hansoh Pharmaceutical (03692), and WuXi AppTec (603259) (02359) [1] - The company also expresses optimism for Innovent Biologics (01801) and Heng Rui Medicine (600276) (01276) [1]